Compare NABL & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | AURA |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.1M | 713.4M |
| IPO Year | 2021 | 2021 |
| Metric | NABL | AURA |
|---|---|---|
| Price | $4.51 | $7.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $8.31 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.8M | 549.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $511,430,000.00 | N/A |
| Revenue This Year | $11.04 | N/A |
| Revenue Next Year | $8.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $2.92 | $4.73 |
| 52 Week High | $9.04 | $9.54 |
| Indicator | NABL | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.40 | 48.64 |
| Support Level | $4.15 | $6.61 |
| Resistance Level | $5.06 | $7.04 |
| Average True Range (ATR) | 0.32 | 0.31 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 53.84 | 51.32 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.